Form 4: Emergent BioSolutions Executive Receives RSU Grant

Coleen Glessner, EVP of Quality & Ethics at Emergent BioSolutions, was granted 100,111 restricted stock units following shareholder approval of the company's incentive plan.

Summary

• Coleen Glessner, EVP of Quality & Ethics and CPL, acquired 100,111 restricted stock units (RSUs) on April 29, 2026.
• The grant was contingent upon shareholder approval of the Amended 2006 Stock Incentive Plan, which was secured on the transaction date.
• The RSUs vest in three equal annual installments, subject to continued service with the company.
• Following this transaction, the reporting person's total beneficial ownership of common stock increased to 204,219 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Successful shareholder approval of the Amended Stock Incentive Plan provides the company with necessary tools for talent retention.

Negatives

• The issuance of 100,111 RSUs results in potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon continued service, creating potential retention risk if the executive departs before the three-year period concludes.

Future Outlook

The RSUs are scheduled to vest in three annual installments, incentivizing the executive's continued tenure and performance over the next three years.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice in the biotechnology sector to align executive incentives with long-term R&D and commercial milestones.

Comparison to Industry Standards

• The use of multi-year vesting schedules for RSUs is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.
• The reliance on shareholder approval for incentive plan amendments aligns with best practices for transparency and governance.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon the eventual vesting and conversion of RSUs into common stock.

Next Steps

• Vesting of the first installment of the 100,111 RSUs on the first anniversary of the approval date.

Key Dates

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Transaction, Restricted Stock Units, Executive Compensation